<DOC>
	<DOC>NCT01525550</DOC>
	<brief_summary>The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.</brief_summary>
	<brief_title>A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description>This study is being conducted to meet regulatory post-marketing commitments.</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma, Islet Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically or cytologically proven diagnosis of welldifferentiated pancreatic neuroendocrine tumor (according to World Health Organization [WHO 2000] classification). Disease progression within 12 months prior to study enrollment. Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent. Patients with poorly differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification). Prior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth factor (VEGF) angiogenesis inhibitors, non VEGF targeted angiogenesis inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>neuroendocrine tumors</keyword>
	<keyword>adenoma islet cells</keyword>
	<keyword>carcinoma islet cells</keyword>
	<keyword>pancreatic neoplasms</keyword>
	<keyword>angiogenesis inhibitors</keyword>
	<keyword>sunitinib</keyword>
	<keyword>neoplasms</keyword>
	<keyword>carcinoma</keyword>
	<keyword>adenoma</keyword>
</DOC>